Category:Charles_A._DinarelloCharles_DinarelloCharles_A._Dinarello%EC%B0%B0%EC%8A%A4_%EB%94%94%EB%82%98%EB%A0%90%EB%A1%9CCharles_Dinarello%D0%94%D0%B8%D0%BD%D0%B0%D1%80%D0%B5%D0%BB%D0%BB%D0%BE,_%D0%A7%D0%B0%D1%80%D0%BB%D1%8C%D0%B7Q834442%E6%9F%A5%E5%B0%94%E6%96%AF%C2%B7%E8%BF%AA%E7%BA%B3%E9%9B%B7%E7%BD%97
about
sameAs
Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase–dependent DC functions and regulates experimental graft-versus-host disease in miceIL-32 synergizes with nucleotide oligomerization domain (NOD) 1 and NOD2 ligands for IL-1beta and IL-6 production through a caspase 1-dependent mechanismThe IL-36 receptor pathway regulates Aspergillus fumigatus-induced Th1 and Th17 responsesA complex of the IL-1 homologue IL-1F7b and IL-18-binding protein reduces IL-18 activity.Interleukin-1 in the pathogenesis and treatment of inflammatory diseasesReactive oxygen species-independent activation of the IL-1beta inflammasome in cells from patients with chronic granulomatous diseaseDifferential release of chromatin-bound IL-1alpha discriminates between necrotic and apoptotic cell death by the ability to induce sterile inflammationIL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiationTreating rheumatological diseases and co-morbidities with interleukin-1 blocking therapiesGeneration and characterization of mice transgenic for human IL-18-binding protein isoform aIL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's diseaseThe interleukin-1 family: 10 years of discoveryIL-37 requires the receptors IL-18Rα and IL-1R8 (SIGIRR) to carry out its multifaceted anti-inflammatory program upon innate signal transductionNeuroinflammation in Alzheimer's diseaseInterleukin-32: a cytokine and inducer of TNFalphaMycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-gamma-dependent mechanismA polysaccharide virulence factor from Aspergillus fumigatus elicits anti-inflammatory effects through induction of Interleukin-1 receptor antagonistIL-37 inhibits inflammasome activation and disease severity in murine aspergillosisRat interleukin-18 binding protein: cloning, expression, and characterizationOzone exposure of macrophages induces an alveolar epithelial chemokine response through IL-1alphaIL-1 is required for tumor invasiveness and angiogenesisCombined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy aloneEnhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failureInnate immune response of human alveolar macrophages during influenza A infectionImmunological and inflammatory functions of the interleukin-1 familyBiologic basis for interleukin-1 in diseaseInterleukin 32 (IL-32) contains a typical α-helix bundle structure that resembles focal adhesion targeting region of focal adhesion kinase-1.The unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice.Eukaryotic translation initiation factor 5A small interference RNA-liposome complexes reduce inflammation and increase survival in murine models of severe sepsis and acute lung injuryIL-1α is a DNA damage sensor linking genotoxic stress signaling to sterile inflammation and innate immunity.Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production.Triggering receptor expressed on myeloid cells-1 (TREM-1) amplifies the signals induced by the NACHT-LRR (NLR) pattern recognition receptors.Functional reconstitution and regulation of IL-18 activity by the IL-18R beta chain.Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and β-cell protectionProteinase 3 is an IL-32 binding proteinVorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trialInterleukin-1 induces a shock-like state in rabbits: synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition.Intravitreal anakinra inhibits choroidal neovascular membrane growth in a rat model.Interleukin-1 gene expression in rabbit vascular tissue in vivo.Interleukin-18 and interleukin-1 beta: two cytokine substrates for ICE (caspase-1).
P50
Q24288997-896BEAB2-B7E3-4FC8-A9A7-1C824717E254Q24293227-CD9B62A3-8911-4832-BF88-72CB72450470Q24303676-CAAF353A-0142-4D38-8B32-0A4B33FE1DACQ24536244-044DD155-8162-4455-9182-8EB4386FEFA7Q24606766-BC08867C-B2BF-4EAE-AE3F-7DF2F6EC897FQ24624942-45EC0CC3-15A3-4D38-8582-241230EA4626Q24646390-1352BCFF-B31F-447C-BF06-EB5B8A3B0210Q24649009-9259AB82-037B-4126-92CB-0830C5C8057BQ26799747-9400BA4C-35AB-498B-92ED-7723BAE8E81AQ28205411-040C4D72-5AA5-4DFF-9BB5-046F7919A6ABQ28208629-621BD689-336B-443D-AF25-96252BC2600FQ28243296-F15C2658-CEA9-4AE5-B843-8053B386B7E8Q28258076-F3186BCE-D4B6-4600-93F8-F0256DFC2D04Q28259238-C1116B19-06AF-4411-97A1-D168E96D6B37Q28303648-F129F347-DDC4-4863-BFF8-82DC9684B993Q28469036-7CCB37EF-D935-49BB-8C28-509A45BEFAF9Q28540595-EBF95125-CB18-4B57-9F02-3B0131A7C31DQ28544789-E7A59217-ADC9-4131-B891-A8CE1B85077DQ28572202-43DE3FB6-D287-4A9B-97C8-AEE3084FE53AQ28573033-A5288DA4-A705-4AEC-8751-E87E3CAC889DQ28594748-1DB4BF51-5E1B-4FAB-89C8-39A0AD67BEBCQ28710288-7451122C-542D-4317-A150-3AEB000B7AA1Q28731260-52A66477-EAFE-4EBE-8A36-E0719A070D7FQ28731580-541FE686-89EB-4782-8518-444180D1E672Q29619669-5274ADA8-AC90-4E19-ADF5-181450CB7B94Q29619853-45F0E53B-3AAE-4A4D-9FA0-6986247C95A8Q30411120-527E86E9-9B11-4A0B-BA78-C7260C40348DQ30435990-69E72973-7DB0-4E4F-A01F-D9AC2916207FQ30436677-29359F0F-9093-4458-92CD-798358868FDDQ30666883-5C7B1D81-5C7B-4998-93DE-4A8F13BB8882Q30718083-E09FC55D-9E34-4A27-BD3B-55DB374F388AQ31057747-E1D1CD09-39A1-4011-8E3C-97BE2CA3DD5EQ31837208-CB8EDE6B-7D7E-47C2-97FC-8329FBD9CCE5Q32945672-1C7677D4-23ED-46DB-9937-A6D4A30662FFQ33234335-58C8E408-E488-41DA-B75F-F15D84C5FCB6Q33411822-2BB4B0E0-09BF-4816-8F84-A602C9A479E0Q33416013-3830BE21-8FDC-4B0A-BCE0-1FBA672771AEQ33479625-251E340C-0C7A-453C-A73B-4FA05C138F3AQ33528100-8D92CB21-B7B0-4E87-A73C-A1C0673D86DBQ33541966-F7540EC5-795E-44AE-8AD0-52C8E69EDA7C
P50
description
American immunologist
@en
Amerikaans immunoloog
@nl
US-amerikanischer Immunologe
@de
imunolojiste american
@lfn
usona imunologo
@eo
name
Charles A. Dinarello
@da
Charles A. Dinarello
@en
Charles A. Dinarello
@es
Charles A. Dinarello
@ga
Charles A. Dinarello
@hu
Charles A. Dinarello
@it
Charles A. Dinarello
@nb
Charles A. Dinarello
@nl
Charles A. Dinarello
@nn
Charles A. Dinarello
@sl
type
label
Charles A. Dinarello
@da
Charles A. Dinarello
@en
Charles A. Dinarello
@es
Charles A. Dinarello
@ga
Charles A. Dinarello
@hu
Charles A. Dinarello
@it
Charles A. Dinarello
@nb
Charles A. Dinarello
@nl
Charles A. Dinarello
@nn
Charles A. Dinarello
@sl
altLabel
C A Dinarello
@en
C Dinarello
@en
C. A. Dinarello
@en
C. Dinarello
@en
Charles A Dinarello
@en
Charles A. Dinarello
@de
Charles Anthony Dinarello
@de
Charles Anthony Dinarello
@en
Charles Dinarello
@en
Dinarello C
@en
prefLabel
Charles A. Dinarello
@da
Charles A. Dinarello
@en
Charles A. Dinarello
@es
Charles A. Dinarello
@ga
Charles A. Dinarello
@hu
Charles A. Dinarello
@it
Charles A. Dinarello
@nb
Charles A. Dinarello
@nl
Charles A. Dinarello
@nn
Charles A. Dinarello
@sl
P108
P166
P1006
P214
P227
P244
P268
P269
P1006
P101
P166
P19
P21
P213
0000 0001 1672 7958